Intercept Pharmaceuticals, Inc.
(NASDAQ : ICPT)

( )
ICPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 3.51%52.430.9%$1363.76m
JNJJohnson & Johnson 1.74%176.970.7%$1352.49m
BMYBristol-Myers Squibb Co. 0.36%76.231.0%$1197.90m
ABBVAbbVie, Inc. -0.53%150.921.9%$1137.44m
MRKMerck & Co., Inc. 1.26%93.250.7%$1136.00m
LLYEli Lilly & Co. 4.49%299.111.1%$892.99m
AZNAstraZeneca Plc 2.59%66.211.0%$517.65m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.65%141.960.0%$458.27m
VERUVeru, Inc. -6.37%13.380.0%$318.66m
NVSNovartis AG 0.86%89.410.2%$251.17m
GSKGlaxoSmithKline Plc 2.23%44.530.2%$243.21m
HZNPHorizon Therapeutics Plc 1.13%90.355.4%$200.40m
NVONovo Nordisk A/S 3.49%107.680.1%$190.60m
SGENSeagen Inc. -2.10%139.645.7%$181.75m
VTRSViatris, Inc. 0.94%11.800.0%$166.13m

Company Profile

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.